GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate
- Conditions
- Influenza
- Interventions
- Biological: Candidate Influenza Vaccine GSK1247446A - 3 different formulationsBiological: Fluarix TM
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3124
- Registration Number
- NCT00321763
- Locations
- π¬π§
GSK Investigational Site, Waterloo, Liverpool, United Kingdom
SB-681323 In Subjects With Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00320450
- Locations
- π¬π§
GSK Investigational Site, Sheffield, United Kingdom
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
- Conditions
- HIV Infection
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00321438
- Locations
- πΊπΈ
GSK Investigational Site, Hampton, Virginia, United States
Study to Evaluate an Influenza Vaccine Candidate
- Conditions
- Influenza
- Interventions
- Biological: Candidate Influenza Vaccine GSK1247446A - 2 different formulationsBiological: FluarixTM
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1220
- Registration Number
- NCT00321373
- Locations
- π¬π·
GSK Investigational Site, Thessaloniki, Greece
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
- Conditions
- Thromboembolism
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00320424
- Locations
GSK Investigational Site
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 296
- Registration Number
- NCT00320385
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
- Conditions
- Thrombosis, Venous
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT00320398
- Locations
GSK Investigational Site
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT00320411
- Locations
GSK Investigational Site
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
- Conditions
- DiphtheriaHepatitis BTetanusPoliomyelitisAcellular Pertussis
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 415
- Registration Number
- NCT00320463
- Locations
- π·πΊ
GSK Investigational Site, Syktyvkar, Russian Federation
Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects
- Conditions
- HIV Infection
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00320307
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom